A gene variant near ATM is significantly associated with metformin treatment response In type 2 diabetes: A replication and meta-analysis of five cohorts

Diabetologia

Volumn 55, Issue 7, 2012, Pages 1971-1977

  Van Leeuwen, N ^a   Nijpels, G ^b   Becker, M L ^c   Deshmukh, H ^d   Zhou, K ^d   Stricker, B H C ^c   Uitterlinden, A G ^c   Hofman, A ^c   Van 'T Riet, E ^b   Palmer, C N A ^d   Guigas, B ^a   Slagboom, P E ^a,e   Durrington, P ^f   Calle, R A ^g   Neil, A ^h   Hitman, G ⁱ   Livingstone, S J ^d   Colhoun, H ^d   Holman, R R ^j,k   McCarthy, M I ^j,k,l   Dekker, J M ^b   'T Hart, L M L ^a   Pearson, E R ^d   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Molecular Epidemiology ^*  (Netherlands)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g Pfizer Ltd   (United States)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^j CHURCHILL HOSPITAL   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Genetics of type 2 diabetes; Human; Meta analysis; Metformin; Oral pharmacological agents

Indexed keywords

HEMOGLOBIN A1C; METFORMIN;

ARTICLE; ATAXIA TELANGIECTASIA MUTATED GENE; GENE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HUMAN; META ANALYSIS; MONOTHERAPY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNITED KINGDOM;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84866319096     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2537-x     Document Type: Article

References (17)

1. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30
2. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607-614
3. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223-228
4. Zhou G, Myers R, Li Y et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174
5. Hawley SA, Ross FA, Chevtzoff C et al (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11:554-565
6. Shaw RJ, Lamia KA, Vasquez D et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646
7. Foretz M, Hebrard S, Leclerc J et al (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120:2355-2369
8. Zhou K, Bellenguez C, Spencer CC et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43:117-120
9. Fu X, Wan S, Lyu YL, Liu LF, Qi H (2008) Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS One 3:e2009
10. Suzuki A, Kusakai G, Kishimoto A et al (2004) IGF-1 phosphorylates AMPK-alpha subunit in ATM-dependent and LKB1-independent manner. Biochem Biophys Res Commun 324:986-992
11. Florez JC, Jablonski K, Taylor A, Pollin T, Shudiner A, Diabetes Prevention Program Research Group (2011) The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes 60:A386 (Abstract)
12. Welschen L (2008) Disease management for patients with type 2 diabetes: towards patient empowerment. Int J Integr Care 8:e69
13. Hofman A, van Duijn CM, Franco OH et al (2011) The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 26:657-686
14. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696
15. Richards JB, Rivadeneira F, Inouye M et al (2008) Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371:1505-1512
16. Wang Q, Cai Y, Van de Casteele M, Pipeleers D, Ling Z (2011) Interaction of glibenclamide and metformin at the level of translation in pancreatic beta cells. J Endocrinol 208:161-169
17. American Diabetes Association (2011) Standards of medical care in diabetes: 2011. Diabetes Care 34(Suppl 1):S11-S61